Nov. 10 at 3:17 PM
$CELZ The recent 10Q gave a good snap shot of CELZ’s warrant landscape and future dilution. Over the next year or two, CELZ’s share count will almost certainly double as the already-paid-for and low-priced warrants convert into stock.
This dilution, however, is already priced in and already paid for.
Cash today (pro forma) ≈
$9.1 M (Sept 30 balance + Oct net proceeds). If every warrant priced around today’s share level were exercised, CELZ would receive an additional
$12 – 13 million in cash and issue about 3.9 million new shares.
So, for the next stage of CELZ’s development float will most likely end up around 7.5 M OS with roughly
$22 million cash to fund future clinical work. That float is still tiny and the cash runway is great. If science bears out, CELZ has all of the ingredients for huge break out.
Bring on the clinical trial updates!
